Since the beginning of the year, there have been a number of treatment pipeline updates from pharmaceutical/biotech companies and academic investigators developing therapies for Friedreich's Ataxia. Join FARA for a virtual office hours session on Wednesday, April 6 at noon (ET) or Tuesday, April 12th at 7pm (ET) to learn more about this progress in the treatment pipeline. During these one-hour sessions, FARA Chief Executive Officer, Jen Farmer and FARA Chief Scientific Officer, Barbara Tate, PhD will summarize the latest news and address your key questions.
In the interest of facilitating meaningful discussion between session attendees and FARA, please submit your questions in advance, by Friday, April 1,
here. Each session will be capped at 50 attendees. To allow for the maximum participation across families, please limit your registration to one person and one session per family.
Some of the news that will be covered includes:
- Reata Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results and Provides an Update on Clinical Development Programs
- LEXEO Announces FDA Clearance of IND Application for LX2006 for Friedreich’s Ataxia Cardiomyopathy
- Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTAC™ Molecule for Friedreich Ataxia
